보고서 요약(국문)

개요
글로벌 암 줄기세포 치료 시장은 2023년 YY백만 달러에 도달했으며, 2024년부터 2031년까지 연평균 성장률(CAGR) YY%로 성장하여 2031년에는 YY백만 달러에 이를 것으로 예상됩니다.
줄기세포 치료는 염증을 줄이고 면역 체계를 조절하여 손상된 세포를 복구하는 재생 의학으로, 다양한 질환에 대한 효과적인 치료 옵션입니다. 줄기세포 이식은 방사선 치료나 화학 요법으로 조혈 줄기세포가 파괴된 환자에게 조혈 줄기세포를 복원하는 암 치료법입니다.
이 치료법은 백혈병, 림프종, 신경모세포종, 다발성 골수종 치료에 사용됩니다. 줄기세포 이식에서 환자는 정맥을 통해 건강한 조혈 줄기세포를 이식받으며, 이식된 줄기세포는 골수로 이동하여 치료로 파괴된 세포를 대체합니다. 이식은 자가 이식, 동종 이식 또는 동계 이식일 수 있습니다.

시장 동향: 성장 동력 및 제약 요인
암 발병률 증가
효과적인 질병 치료로 인한 전 세계적인 암 발병률 증가는 암 줄기세포 시장의 수요를 견인하고 있습니다. 암 줄기세포 치료는 특정 암세포를 표적으로 삼아 치료 후 남은 암을 제거하는 것을 목표로 합니다. 이 치료에는 유전자 변형, 세포 분리, 맞춤형 치료 계획 수립 등 복잡한 과정이 포함됩니다. 이러한 요소들이 종합적으로 암 줄기세포 시장의 성장에 기여하고 있습니다.
예를 들어, 미국 암 협회(American Cancer Society)는 매년 미국 내 신규 암 발병 건수와 사망자 수를 추산하고, 중앙 암 등록 기관에서 수집한 발생률 데이터와 국립보건통계센터(National Center for Health Statistics)에서 수집한 사망률 데이터를 활용하여 인구 기반 암 발생 및 결과에 대한 최신 데이터를 집계합니다. 2023년에는 미국에서 1,958,310건의 신규 암 발병 사례와 609,820명의 암 사망자가 발생할 것으로 예상되었습니다.

치료 관련 높은 비용
암 줄기세포 치료법 개발에는 광범위한 연구, 임상 시험 및 전임상 연구가 필요하며, 이로 인해 높은 비용과 지출 증가가 발생합니다. 이는 승인 후 약물의 소매 가격 상승으로 이어져 암 줄기세포 시장의 성장을 제한합니다. 높은 암 치료 비용은 암 줄기세포 치료 개발에 있어 중요한 장벽입니다.

본 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
글로벌 암 줄기세포 치료 시장은 치료 유형, 암 유형, 최종 사용자 및 지역별로 세분화됩니다.
치료 유형 부문에서 자가 줄기세포 이식은 암 줄기세포 치료 시장 점유율의 약 52.3%를 차지했습니다.
자가 줄기세포 이식은 일반적으로 고용량의 화학 요법과 방사선 치료를 받아야 하는 환자에게 사용됩니다. 이러한 치료는 골수 손상을 유발할 수 있습니다. 자가 줄기세포 이식은 손상된 골수를 대체하는 데 도움을 줍니다.

예를 들어, 특정 암 및 희귀 질환에 중점을 둔 상업 단계 바이오제약 회사인 BioLineRx Ltd.는 2023년 9월 미국 식품의약국(FDA)이 다발성 골수종 환자의 말초 혈액으로 조혈 줄기세포를 동원하여 채집하고 자가 이식하는 데 사용되는 아펙스다(모틱사포르티드)와 필그라스팀(G-CSF) 병용 요법을 승인했다고 발표했습니다. 아펙스다는 피하 주사로 투여됩니다.
지역 분석
북미는 예측 기간 동안 전체 시장 점유율의 약 43.4%를 차지할 것으로 예상됩니다.
북미는 잘 구축된 의료 시스템, 미국과 캐나다와 같은 선진 경제국의 만성 질환 치료 투자, 주요 제약 회사 및 연구 센터의 존재 등의 요인으로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다. 또한, 기술적으로 발전된 의료 인프라와 생의학 연구 센터들이 다양한 암 치료법을 적극적으로 연구하고 있어 시장 성장에 기여하고 있습니다.
예를 들어, 2024년 3월 스탠퍼드 의과대학은 미국 식품의약국(FDA)의 승인을 받은 새로운 세포 기반 치료법을 사용하여 전이성 흑색종 환자를 치료한 미국 최초의 센터가 되었습니다. 면역 요법에 내성을 보이는 진행성 흑색종 환자들에게 희망을 주는 이 치료법은 FDA 승인을 받은 최초의 고형암 세포 기반 치료법입니다.
코로나19 영향 분석
코로나19 팬데믹은 시장에 상당한 영향을 미쳐 의료 및 생의학 연구에 대한 관심이 높아졌습니다. 자금 지원 기관과 정부는 암 줄기세포 치료를 포함한 연구에 자원을 할당했습니다. 또한 팬데믹은 연구자들이 적응하고 혁신하도록 촉진하여 새로운 전략과 협력을 이끌어냈습니다.

시장 세분화
제품 유형별
• 자가 줄기세포 이식
• 동종 줄기세포 이식
• 동계 줄기세포 이식
• 기타
암 유형별
• 유방암
• 방광암
• 혈액암
• 폐암
• 뇌암
• 기타
최종 사용자별
• 병원
• 클리닉
• 학술 및 연구 기관
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 한국
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Thermo Fisher Scientific, Inc., Advanced Cell Diagnostics, Silicon Biosystems, Celularity Inc., Gamida Cell Ltd, Sumitomo 등이 있습니다. 다이닛폰 제약(Dainippon Pharma Co. Ltd), 머크(Merck KGaA), 제넨텍(Genentech Inc.), 아스텔라스 제약(Astellas Pharma Inc.), 노바딥 바이오사이언스(Novadip Biosciences) 등이 주요 기업입니다.

주요 개발 사항
 2024년 2월, 툼바이 대학 병원(Thumbay University Hospital)은 아즈만 알 주르프에 위치한 툼바이 대학 암 센터를 개원했습니다. 모든 시설을 갖춘 이 센터는 2024년 2월 말까지 운영을 시작할 예정입니다. 북부 에미레이트 지역의 암 치료 및 검진 수요 증가에 따라 이러한 센터가 설립되었습니다. 이 암 센터는 다학제적 치료에 중점을 둔 합리적인 가격의 암 치료를 제공할 것입니다.

 2024년 1월, 글렌마크 제약(Glenmark Pharma)은 이크노스 사이언스(Ichnos Science)와 협력하여 암 치료에서 약물 전달을 향상시키는 이크노스 글렌마크 이노베이션(Ichnos Glenmark Innovation, IGI)을 발표했습니다.

보고서 구매 이유

• 치료 유형, 암 유형, 최종 사용자 및 지역별 글로벌 암 줄기세포 치료 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해

• 트렌드 및 공동 개발 분석을 통해 상업적 기회를 식별하기 위해

• 모든 세그먼트를 포함한 암 줄기세포 치료 시장 수준의 다양한 데이터 포인트가 담긴 엑셀 데이터 시트

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공

글로벌 암 줄기세포 치료 시장 보고서는 약 64개의 표, 61개의 그림, 186페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Cancer Stem Cell Therapy Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
Stem cell therapy is a regenerative medicine that repairs damaged cells by reducing inflammation and modulating the immune system, making it a viable treatment option for various medical conditions. Stem cell transplantation is a cancer treatment that restores stem cells responsible for blood-forming in patients who have had their blood-forming stem cells destroyed through radiotherapy or chemotherapy.
This treatment is used to treat leukaemia, lymphoma, neuroblastoma, and multiple myeloma. In a stem cell transplant, the patient receives healthy blood-forming stem cells through a vein, which travel to the bone marrow to replace the cells destroyed by treatment. Transplants can be autologous, allogeneic, or syngeneic.
Market Dynamics: Drivers & Restraints
Rise in the prevalence of cancer cases
The global increase in cancer cases due to efficient disease treatment is driving demand for the cancer stem cells market. Cancer stem cell therapy targets specific cancer cells to eliminate post-treatment cancer. It involves intricate processes like genetic modulation, cell isolation, and personalized treatment planning. These factors collectively contribute to the growth of the cancer stem cell market.
For instance, each year, the American Cancer Society estimates the number of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries and mortality data collected by the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States.

High costs associated with the treatment
Cancer stem cell therapy development necessitates extensive research, clinical trials, and preclinical investigations, resulting in high costs and increased expenditure. This leads to a higher retail price of the drug upon approval, limiting the growth of the cancer stem cell market. The high cost of cancer treatment is a significant barrier to its development.

For more details on this report – Request for Sample
Segment Analysis
The global cancer stem cell therapy market is segmented based on therapy type, cancer type end-user and region.
The autologous stem cell transplants from the therapy type segment accounted for approximately 52.3% of the cancer stem cell therapy market share
The autologous stem cell transplants from the therapy type segment accounted for approximately 42.3%. Autologous stem cell transplants are typically used in people who need to undergo high doses of chemotherapy and radiation to cure their diseases. These treatments are likely to damage the bone marrow. An autologous stem cell transplant helps to replace the damaged bone marrow.
For instance, in September 2023, BioLineRx Ltd. a commercial-stage biopharmaceutical company focused on certain cancers and rare diseases, announced that the U.S. Food and Drug Administration (FDA) has approved APHEXDA (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA is administered by injection, for subcutaneous use.
Geographical Analysis
North America is estimated to hold about 43.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the established healthcare sector, developed economies like the US and Canada investing in chronic disease treatment, and the presence of major pharmaceutical companies and research centers. Also, technologically advanced healthcare infrastructure and biomedical research centers are actively researching various cancer treatment methods, contributing to the market's growth.
For instance, in March 2024, Stanford Medicine became the first center in the nation to treat a patient with metastatic melanoma using a new cell-based therapy approved by the Food and Drug Administration. The therapy, which offers hope for people with advanced melanoma whose cancers have resisted immunotherapies, is the first cell-based therapy approved by the FDA to treat solid tumors.
Covid 19 Impact Analysis
The COVID-19 pandemic significantly impacted the market, leading to increased focus on healthcare and biomedical research. Funding agencies and governments allocated resources for research, including cancer stem cell therapy. The pandemic also prompted researchers to adapt and innovate, resulting in new strategies and collaborations.
Market Segmentation
By Product Type
• Autologous Stem Cell Transplants
• Allogeneic Stem Cell Transplants
• Syngeneic Stem Cell Transplants
• Others
By Cancer Type
• Breast Cancer
• Bladder Cancer
• Blood Cancer
• Lung Cancer
• Brain Cancer
• Others
By End User
• Hospitals
• Clinics
• Academic and Research Institutes
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Thermo Fisher Scientific, Inc., Advanced Cell Diagnostics, Silicon Biosystems, Celularity Inc., Gamida Cell Ltd, Sumitomo Dainippon Pharma Co. Ltd, Merck KGaA, Genentech Inc., Astellas Pharma Inc., Novadip Biosciences among others.
Key Developments
 In February 2024, Thumbay University Hospital launched the Cancer Center at Thumbay University in Al Jurf, Ajman. The fully equipped centre will be active by the end of February 2024. The rising demand for cancer treatment and screening in the Northern Emirates resulted in the launch of these centres. The cancer centre will offer affordable cancer care focusing on multidisciplinary treatment.
 In January 2024, Glenmark Pharma, in collaboration with Ichnos Science, announced the Ichnos Glenmark Innovation (IGI) to increase drug delivery in cancer treatment.

Why Purchase the Report?
• To visualize the global cancer stem cell therapy market segmentation based on therapy type, cancer type, end user and region as well as understand key commercial assets and players.
• identify commercial opportunities by analyzing trends and co-development.
• excel data sheet with numerous data points of the cancer stem cell therapy market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global cancer stem cell therapy market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy Type
3.2. Snippet by Cancer Type
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of cancer cases
4.1.1.2. Rise of advancements in treatment options
4.1.2. Restraints
4.1.2.1. High cost of treatment
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Therapy Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
7.1.2. Market Attractiveness Index, By Therapy Type
7.2. Autologous Stem Cell Transplants*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Allogeneic Stem Cell Transplants
7.4. Syngeneic Stem Cell Transplants
7.5. Others
8. By Cancer Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.1.2. Market Attractiveness Index, By Cancer Type
8.2. Breast Cancer*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Bladder Cancer
8.4. Blood Cancer
8.5. Lung Cancer
8.6. Brain Cancer
8.7. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinics
9.4. Medical research institutes
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. South Korea
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Thermo Fisher Scientific, Inc*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Advanced Cell Diagnostics
12.3. Silicon Biosystems
12.4. Celularity Inc
12.5. Gamida Cell Ltd
12.6. Sumitomo Dainippon Pharma Co. Ltd
12.7. Merck KGaA
12.8. Genentech Inc
12.9. Astellas Pharma Inc
12.10. Novadip Biosciences
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Thermo Fisher Scientific, Inc, 4.	Key Developments, Advanced Cell Diagnostics, Silicon Biosystems, Celularity Inc, Gamida Cell Ltd, Sumitomo Dainippon Pharma Co. Ltd, Merck KGaA, Genentech Inc, Astellas Pharma Inc, Novadip Biosciences

표 목록 (Tables)

List of Tables

Table 1 Global Cancer Stem Cell Therapy Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Cancer Stem Cell Therapy Market Value, By Cancer Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Cancer Stem Cell Therapy Market Value, By End User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Cancer Stem Cell Therapy Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Cancer Stem Cell Therapy Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Cancer Stem Cell Therapy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 7 Global Cancer Stem Cell Therapy Market Value, By Cancer Type, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Cancer Stem Cell Therapy Market Value, By Cancer Type, 2022-2031 (US$ Million)

Table 9 Global Cancer Stem Cell Therapy Market Value, By End User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Cancer Stem Cell Therapy Market Value, By End User, 2022-2031 (US$ Million)

Table 11 Global Cancer Stem Cell Therapy Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Cancer Stem Cell Therapy Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Cancer Stem Cell Therapy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 14 North America Cancer Stem Cell Therapy Market Value, By Cancer Type, 2022-2031 (US$ Million)

Table 15 North America Cancer Stem Cell Therapy Market Value, By End User, 2022-2031 (US$ Million)

Table 16 North America Cancer Stem Cell Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 17 Asia-Pacific Cancer Stem Cell Therapy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 18 Asia-Pacific Cancer Stem Cell Therapy Market Value, By Cancer Type, 2022-2031 (US$ Million)

Table 19 Asia-Pacific Cancer Stem Cell Therapy Market Value, By End User, 2022-2031 (US$ Million)

Table 20 Asia-Pacific Cancer Stem Cell Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Cancer Stem Cell Therapy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 22 Europe Cancer Stem Cell Therapy Market Value, By Cancer Type, 2022-2031 (US$ Million)

Table 23 Europe Cancer Stem Cell Therapy Market Value, By End User, 2022-2031 (US$ Million)

Table 24 Europe Cancer Stem Cell Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 25 South America Cancer Stem Cell Therapy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 26 South America Cancer Stem Cell Therapy Market Value, By Cancer Type, 2022-2031 (US$ Million)

Table 27 South America Cancer Stem Cell Therapy Market Value, By End User, 2022-2031 (US$ Million)

Table 28 South America Cancer Stem Cell Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East and Africa Cancer Stem Cell Therapy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 30 Middle East and Africa Cancer Stem Cell Therapy Market Value, By Cancer Type, 2022-2031 (US$ Million)

Table 31 Middle East and Africa Cancer Stem Cell Therapy Market Value, By End User, 2022-2031 (US$ Million)

Table 32 Middle East and Africa Cancer Stem Cell Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 33 Thermo Fisher Scientific, Inc: Overview

Table 34 Thermo Fisher Scientific, Inc: Product Portfolio

Table 35 Thermo Fisher Scientific, Inc: Key Developments

Table 36 Advanced Cell Diagnostics: Overview

Table 37 Advanced Cell Diagnostics: Product Portfolio

Table 38 Advanced Cell Diagnostics: Key Developments

Table 39 Silicon Biosystems: Overview

Table 40 Silicon Biosystems: Product Portfolio

Table 41 Silicon Biosystems: Key Developments

Table 42 Celularity Inc: Overview

Table 43 Celularity Inc: Product Portfolio

Table 44 Celularity Inc: Key Developments

Table 45 Gamida Cell Ltd: Overview

Table 46 Gamida Cell Ltd: Product Portfolio

Table 47 Gamida Cell Ltd: Key Developments

Table 48 Sumitomo Dainippon Pharma Co. Ltd: Overview

Table 49 Sumitomo Dainippon Pharma Co. Ltd: Product Portfolio

Table 50 Sumitomo Dainippon Pharma Co. Ltd: Key Developments

Table 51 Merck KGaA: Overview

Table 52 Merck KGaA: Product Portfolio

Table 53 Merck KGaA: Key Developments

Table 54 Genentech Inc: Overview

Table 55 Genentech Inc: Product Portfolio

Table 56 Genentech Inc: Key Developments

Table 57 Astellas Pharma Inc: Overview

Table 58 Astellas Pharma Inc: Product Portfolio

Table 59 Astellas Pharma Inc: Key Developments

Table 60 Novadip Biosciences: Overview

Table 61 Novadip Biosciences: Product Portfolio

Table 62 Novadip Biosciences: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 2 Global Cancer Stem Cell Therapy Market Share, By Product Type, 2023 & 2031 (%)

Figure 3 Global Cancer Stem Cell Therapy Market Share, By Cancer Type, 2023 & 2031 (%)

Figure 4 Global Cancer Stem Cell Therapy Market Share, By End User, 2023 & 2031 (%)

Figure 5 Global Cancer Stem Cell Therapy Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Cancer Stem Cell Therapy Market Y-o-Y Growth, By Product Type, 2023-2031 (%)

Figure 7 Autologous Stem Cell Transplants Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 8 Allogeneic Stem Cell Transplants Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 9 Syngeneic Stem Cell Transplants Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 10 Others Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 11 Global Cancer Stem Cell Therapy Market Y-o-Y Growth, By Cancer Type, 2023-2031 (%)

Figure 12 Breast Cancer Cancer Type in Global Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 13 Bladder Cancer Cancer Type in Global Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 14 Blood Cancer Cancer Type in Global Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 15 Lung Cancer Cancer Type in Global Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 16 Brain Cancer Cancer Type in Global Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 17 Others Cancer Type in Global Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 18 Global Cancer Stem Cell Therapy Market Y-o-Y Growth, By End User, 2023-2031 (%)

Figure 19 Hospitals End User in Global Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 20 Clinics End User in Global Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 21 Academic and Research Institutes End User in Global Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 22 Others End User in Global Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 23 Global Cancer Stem Cell Therapy Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 24 North America Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 25 North America Cancer Stem Cell Therapy Market Share, By Product Type, 2023 & 2031 (%)

Figure 26 North America Cancer Stem Cell Therapy Market Share, By Cancer Type, 2023 & 2031 (%)

Figure 27 North America Cancer Stem Cell Therapy Market Share, By End User, 2023 & 2031 (%)

Figure 28 North America Cancer Stem Cell Therapy Market Share, By Country, 2023 & 2031 (%)

Figure 29 Asia-Pacific Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 30 Asia-Pacific Cancer Stem Cell Therapy Market Share, By Product Type, 2023 & 2031 (%)

Figure 31 Asia-Pacific Cancer Stem Cell Therapy Market Share, By Cancer Type, 2023 & 2031 (%)

Figure 32 Asia-Pacific Cancer Stem Cell Therapy Market Share, By End User, 2023 & 2031 (%)

Figure 33 Asia-Pacific Cancer Stem Cell Therapy Market Share, By Country, 2023 & 2031 (%)

Figure 34 Europe Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 35 Europe Cancer Stem Cell Therapy Market Share, By Product Type, 2023 & 2031 (%)

Figure 36 Europe Cancer Stem Cell Therapy Market Share, By Cancer Type, 2023 & 2031 (%)

Figure 37 Europe Cancer Stem Cell Therapy Market Share, By End User, 2023 & 2031 (%)

Figure 38 Europe Cancer Stem Cell Therapy Market Share, By Country, 2023 & 2031 (%)

Figure 39 South America Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 40 South America Cancer Stem Cell Therapy Market Share, By Product Type, 2023 & 2031 (%)

Figure 41 South America Cancer Stem Cell Therapy Market Share, By Cancer Type, 2023 & 2031 (%)

Figure 42 South America Cancer Stem Cell Therapy Market Share, By End User, 2023 & 2031 (%)

Figure 43 South America Cancer Stem Cell Therapy Market Share, By Country, 2023 & 2031 (%)

Figure 44 Middle East and Africa Cancer Stem Cell Therapy Market Value, 2022-2031 (US$ Million)

Figure 45 Middle East and Africa Cancer Stem Cell Therapy Market Share, By Product Type, 2023 & 2031 (%)

Figure 46 Middle East and Africa Cancer Stem Cell Therapy Market Share, By Cancer Type, 2023 & 2031 (%)

Figure 47 Middle East and Africa Cancer Stem Cell Therapy Market Share, By End User, 2023 & 2031 (%)

Figure 48 Thermo Fisher Scientific, Inc: Financials

Figure 49 Advanced Cell Diagnostics: Financials

Figure 50 Silicon Biosystems: Financials

Figure 51 Celularity Inc: Financials

Figure 52 Gamida Cell Ltd: Financials

Figure 53 Sumitomo Dainippon Pharma Co. Ltd: Financials

Figure 54 Merck KGaA: Financials

Figure 55 Genentech Inc: Financials

Figure 56 Astellas Pharma Inc: Financials

Figure 57 Novadip Biosciences: Financials

글로벌 암 줄기세포 치료 시장 – 2024-2031년

Global Cancer Stem Cell Therapy Market - 2024-2031